ClariFlow | Devpost

ClariFlow Kit (Treatment, Tests, and Instructions)
Blood Test Kit

Website Access Password: ClariFlow

Inspiration

Our inspiration stems from SDG 5 and 10, which promotes gender equality and aims to address systemic disparities in access to healthcare, including those experienced by transgender women. Transgender individuals on hormone therapy, especially in countries with limited access to specialized care, face an increased risk of estrogen-associated thrombosis due to elevated estrogen intake. This risk is compounded by a lack of access to affordable, preventative tools and knowledgeable providers, issues made worse by a stark ratio of 1 doctor to every 7,000 transgender women in hormone therapy. ClariFlow was created to bridge this gap through accessible, proactive blood clot prevention that empowers users to monitor and protect their health at home.

How It Works & How We Built It

ClariFlow is a comprehensive clot detection and prevention kit that enables transgender women and other high-risk hormone therapy users to monitor and manage clot risk from home. The kit includes two key diagnostic tools: a D-dimer test to detect clot-related protein fragments in the blood and an APTT (activated partial thromboplastin time) test to measure clotting speed. Users follow clear instructions and symptom guides to interpret their results, with elevated D-dimer levels (above 0.5 ng/L) or fast clotting times (under 25 seconds) indicating a heightened risk. The testing system is designed to be user-friendly and accessible without sending results to a lab. Paired with this diagnostic approach is a targeted enzyme capsule that combines nattokinase (a naturally derived enzyme known to dissolve fibrin in blood clots), clot-safe vitamins, and a smart antifibrinolytic "safety guard." This built-in safety guard monitors the user's blood for signs of excessive thinning. If the blood becomes too thin, the antifibrinolytic automatically stabilizes clotting, using a negative feedback mechanism to prevent uncontrolled bleeding. This dual system—early detection with a controlled therapeutic response—offers peace of mind and continuous protection against silent clot formation.

Challenges We Ran Into

One of our most significant challenges was identifying an enzyme therapy that could provide clot prevention without introducing a substantial risk of internal bleeding. Conventional clot-busting enzymes, such as plasminogen activators, are effective but pose serious bleeding risks when used across the entire circulatory system. Through extensive research, we turned to nattokinase, a naturally sourced enzyme with mild but effective fibrinolytic properties. To further ensure user safety, we integrated a negative feedback safety mechanism using antifibrinolytics—substances that detect when the blood becomes too thin and act to rebuild proper clotting, preventing over-thinning and reducing risk. This dual mechanism allowed us to maintain efficacy without compromising safety.

Accomplishments That We're Proud Of

We are proud to have created ClariFlow, a practical and inclusive health solution that allows marginalized individuals to monitor and address clot risk at home. Our greatest accomplishment lies in bridging gender- and income-based disparities through an affordable, intuitive product that empowers transgender women and others on hormone therapy to manage their health with dignity and confidence. We've succeeded in combining natural biochemistry, diagnostic precision, and digital accessibility into a single product that is both medically sound and socially impactful. Our innovation makes early clot detection and safe intervention possible without requiring constant doctor visits, lab tests, or invasive procedures.

What's Next For ClariFlow

Moving forward, we plan to expand the applicability of ClariFlow to reach other at-risk groups, including menopausal individuals, fertility patients, and those with inherited clotting disorders. Our goals include refining the accuracy and responsiveness of the enzyme capsule's antifibrinolytic safety guard, ensuring broader regulatory compliance, and partnering with manufacturers to scale production. We are also exploring app-based data tracking that lets users log test results, receive automated risk assessments, and connect to local healthcare providers. By continuing to develop ClariFlow into an even more user-centered and medically robust tool, we aim to push forward a future where lifesaving preventative care is accessible to all—regardless of gender, income, or location.